EGFR and neoplasm: This interaction is also pivotal for tumor progression in cancers with WT-RAS, as evidenced by EGFR-mutant lung adenocarcinoma mice harboring PI3Kα-T208D/K227A mutations, where disrupting this interaction inhibits tumor onset and promotes significant tumor regression28.